Simple Ordering: Buy & Bill, Specialty Pharmacy Info, and Inventory Program

We’ve made it simple to get ZILRETTA for your patients

We understand you have an established process for ordering products at your practice, and we’re committed to minimizing any disruption.

How the ZILRETTA Inventory Program Works

The ZILRETTA Inventory Program was designed to address the financial and operational hurdles associated with the traditional buy-and-bill model so that you can focus on delivering care.

Get Started

Contact your Pacira representative. They will set up a meeting with the FFF Enterprises team to walk your practice through the program, discuss the inventory management system requirements, and ensure the program meets your office’s needs.
Receive the Refrigerator

Your practice receives a compact*, state-of-the-art refrigerator that accurately monitors and replenishes stock when needed, as well as manages expiration.
- Reduces administrative burden and ordering complexity
- Automates inventory management and replenishment
- Allows you to spend less time on manual tracking and more time on patient care
Simplify Billing

No upfront cost—you're only invoiced when a ZILRETTA kit is removed from the refrigerator. Prior to administration, be sure to verify your patient’s benefits using FlexForward.
- Submit for reimbursement using the permanent J-code J3304¹
- You will receive an invoice after a kit is removed from the refrigerator
- Submit your payment to FFF Enterprises

Contact a Pacira representative

*RightNow Ready^TM refrigerator measures 28” wide, 26” deep, 56” high

Reference: 1. Centers for Medicare & Medicaid Services. April 2025 HCPCS table of drugs. Updated March 26, 2025. Accessed April 18, 2025. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update

The ZILRETTA Inventory Program is provided through a partnership with FFF Enterprises, Inc., a trusted specialty pharmaceutical distributor.

Indication and Important Safety Information

Indication

ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions

The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.

Please see full Prescribing Information.

Getting ZILRETTA

We’ve made it simple to get ZILRETTA for your patients

How the ZILRETTA Inventory Program Works

Get Started

Receive the Refrigerator

Simplify Billing